Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inhaled Hydrogen Therapy's Effect on Early Recurrences of Atrial Fibrillation Post-ablation. Phase II, Multicenter, Randomized, Controlled, Open-label Clinical Trial

NCT07928622 is registered in ClinicalTrials.gov with University Hospital, Grenoble as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07928622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Inhaled Hydrogen Therapy's Effect on Early Recurrences of Atrial Fibrillation Post-ablation. Phase II, Multicenter, Randomized, Controlled, Open-label Clinical Trial
Lead sponsor
University Hospital, Grenoble
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
September 30, 2029
Enrollment
124 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation ablation

Arms

As registered; 2 arms.

  • Standard of care No intervention

    patients treated with usual care (Standard of Care)

  • H2 ExperimentalHydrogen Gas (H2)

    patient treated with inhaled hydrogen therapy during the perioperative period

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Effectiveness of inhaled hydrogen therapy on early recurrences of atrial fibrillation post-ablation and on the improvement of quality of life at 3 months From baseline (before ablation) to 3 months after ablation

    Composite binary endpoint, reported as the number of participants meeting both criteria: (1) no early recurrence during the blanking period (first 3 months after ablation), where recurrence is defined as any episode of atrial fibrillation, atrial flutter or atrial tachycardia lasting at least 30 seconds; AND (2) improvement in quality of life, defined as an improvement in quality of life, defined as an increase of at least 5 points in the AFEQT overall score (range 0-100; higher scores indicate better quality of life) between baseline and 3 months.

Lead sponsor's other trials

University Hospital, Grenoble, most recent start first.